Ozempic

Riik: Euroopa Liit

keel: inglise

Allikas: EMA (European Medicines Agency)

Osta kohe

Infovoldik Infovoldik (PIL)
03-05-2023
Toote omadused Toote omadused (SPC)
03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande (PAR)
21-02-2018

Toimeaine:

semaglutide

Saadav alates:

Novo Nordisk A/S

ATC kood:

A10BJ06

INN (Rahvusvaheline Nimetus):

semaglutide

Terapeutiline rühm:

Drugs used in diabetes

Terapeutiline ala:

Diabetes Mellitus

Näidustused:

Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

Toote kokkuvõte:

Revision: 10

Volitamisolek:

Authorised

Loa andmise kuupäev:

2018-02-08

Infovoldik

                                45
B. PACKAGE LEAFLET
46
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
OZEMPIC 0.25 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
semaglutide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
–
Keep this leaflet. You may need to read it again.
–
If you have any further questions, ask your doctor, pharmacist or
nurse.
–
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
–
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Ozempic is and what it is used for
2.
What you need to know before you use Ozempic
3.
How to use Ozempic
4.
Possible side effects
5.
How to store Ozempic
6.
Contents of the pack and other information
1.
WHAT OZEMPIC IS AND WHAT IT IS USED FOR
Ozempic contains the active substance semaglutide. It
_ _
helps your body reduce your blood sugar level
only when blood sugar is too high and can help prevent heart disease.
Ozempic is used to treat adults (aged 18 years and older) with type 2
diabetes when diet and exercise
is not enough:
•
on its own – when you cannot use metformin (another diabetes
medicine) or
•
with other medicines for diabetes – when they are not enough to
control your blood sugar levels.
These may be medicines you take by mouth or inject such as insulin.
It is important that you continue with your diet and exercise plan as
told by your doctor, pharmacist or
nurse.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE OZEMPIC
_ _
DO NOT USE OZEMPIC
•
if you are allergic to semaglutide or any of the other ingredients of
this medicine (listed in
section 6).
WARNINGS AND PRECAUTIONS
Talk to your doctor, pharmacist or nurse before using this medicine.
This medicine is not the same as insulin and you should not use it if:
•
you have type 1 diabetes – a condition where your body does no
                                
                                Lugege kogu dokumenti
                                
                            

Toote omadused

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Ozempic 0.25 mg solution for injection in pre-filled pen
Ozempic 0.5 mg solution for injection in pre-filled pen
Ozempic 1 mg solution for injection in pre-filled pen
Ozempic 2 mg solution for injection in pre-filled pen
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Ozempic 0.25 mg
solution for injection
One ml of solution contains 1.34 mg of semaglutide*. One pre-filled
pen contains 2 mg semaglutide*
in 1.5 ml solution. Each dose contains 0.25 mg of semaglutide in 0.19
ml solution.
Ozempic 0.5 mg solution for injection
One ml of solution contains 1.34 mg of semaglutide*. One pre-filled
pen contains 2 mg semaglutide*
in 1.5 ml solution. Each dose contains 0.5 mg of semaglutide in 0.37
ml solution.
Ozempic 1 mg solution for injection
One ml of solution contains 1.34 mg of semaglutide*. One pre-filled
pen contains 4 mg semaglutide*
in 3 ml solution. Each dose contains 1 mg of semaglutide in 0.74 ml
solution.
Ozempic 2 mg solution for injection
One ml of solution contains 2.68 mg of semaglutide*. One pre-filled
pen contains 8 mg semaglutide*
in 3 ml solution. Each dose contains 2 mg of semaglutide in 0.74 ml
solution.
*Human glucagon-like peptide-1 (GLP-1) analogue produced in
_Saccharomyces cerevisiae _
cells
_ _
by
_ _
recombinant DNA technology
_._
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection (injection).
Clear and colourless or almost colourless, isotonic solution; pH=7.4.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Ozempic is indicated for the treatment of adults with insufficiently
controlled type 2 diabetes mellitus
as an adjunct to diet and exercise
•
as monotherapy when metformin is considered inappropriate due to
intolerance or
contraindications
•
in addition to other medicinal products for the treatment of diabetes.
3
For trial results with respect to combinations, effects on glycaemic
control and cardiovascular events,
and the populations studied, see sections 4.4, 
                                
                                Lugege kogu dokumenti
                                
                            

Dokumendid teistes keeltes

Infovoldik Infovoldik bulgaaria 03-05-2023
Toote omadused Toote omadused bulgaaria 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande bulgaaria 21-02-2018
Infovoldik Infovoldik hispaania 03-05-2023
Toote omadused Toote omadused hispaania 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande hispaania 21-02-2018
Infovoldik Infovoldik tšehhi 03-05-2023
Toote omadused Toote omadused tšehhi 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande tšehhi 21-02-2018
Infovoldik Infovoldik taani 03-05-2023
Toote omadused Toote omadused taani 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande taani 21-02-2018
Infovoldik Infovoldik saksa 03-05-2023
Toote omadused Toote omadused saksa 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande saksa 21-02-2018
Infovoldik Infovoldik eesti 03-05-2023
Toote omadused Toote omadused eesti 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande eesti 21-02-2018
Infovoldik Infovoldik kreeka 03-05-2023
Toote omadused Toote omadused kreeka 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande kreeka 21-02-2018
Infovoldik Infovoldik prantsuse 03-05-2023
Toote omadused Toote omadused prantsuse 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande prantsuse 21-02-2018
Infovoldik Infovoldik itaalia 03-05-2023
Toote omadused Toote omadused itaalia 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande itaalia 21-02-2018
Infovoldik Infovoldik läti 03-05-2023
Toote omadused Toote omadused läti 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande läti 21-02-2018
Infovoldik Infovoldik leedu 03-05-2023
Toote omadused Toote omadused leedu 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande leedu 21-02-2018
Infovoldik Infovoldik ungari 03-05-2023
Toote omadused Toote omadused ungari 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande ungari 21-02-2018
Infovoldik Infovoldik malta 03-05-2023
Toote omadused Toote omadused malta 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande malta 21-02-2018
Infovoldik Infovoldik hollandi 03-05-2023
Toote omadused Toote omadused hollandi 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande hollandi 21-02-2018
Infovoldik Infovoldik poola 03-05-2023
Toote omadused Toote omadused poola 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande poola 21-02-2018
Infovoldik Infovoldik portugali 03-05-2023
Toote omadused Toote omadused portugali 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande portugali 21-02-2018
Infovoldik Infovoldik rumeenia 03-05-2023
Toote omadused Toote omadused rumeenia 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande rumeenia 21-02-2018
Infovoldik Infovoldik slovaki 03-05-2023
Toote omadused Toote omadused slovaki 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande slovaki 21-02-2018
Infovoldik Infovoldik sloveeni 03-05-2023
Toote omadused Toote omadused sloveeni 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande sloveeni 21-02-2018
Infovoldik Infovoldik soome 03-05-2023
Toote omadused Toote omadused soome 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande soome 21-02-2018
Infovoldik Infovoldik rootsi 03-05-2023
Toote omadused Toote omadused rootsi 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande rootsi 21-02-2018
Infovoldik Infovoldik norra 03-05-2023
Toote omadused Toote omadused norra 03-05-2023
Infovoldik Infovoldik islandi 03-05-2023
Toote omadused Toote omadused islandi 03-05-2023
Infovoldik Infovoldik horvaadi 03-05-2023
Toote omadused Toote omadused horvaadi 03-05-2023
Avaliku hindamisaruande Avaliku hindamisaruande horvaadi 21-02-2018

Otsige selle tootega seotud teateid

Vaadake dokumentide ajalugu